



Mylan N.V.  
Investor Relations Department  
PO Box 2648  
Portland, OR 97208-2648  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: MYL**


Last Trade:	39.83
Trade Time:	4:00 PM ET May 25, 2017
Change:	0.65  (+1.659%)
Day Range	38.95 - 39.86
52-Week Range	33.60 - 50.40
Volume	4,691,269

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 7,500 marketed products around the world, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS in the developing world depend. We... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 23, 2017*  
[Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin \(TD-4208\) in Several Presentations at 2017 ATS](#)
- May 17, 2017*  
[Theravance Biopharma and Mylan to Present Additional Data for Revefenacin \(TD-4208\) in Several Presentations at 2017 ATS](#)
- May 16, 2017*  
[Mylan to Present at UBS Global Healthcare Conference](#)
- May 16, 2017*  
[Mylan Honors National Women's Health Week to Empower Women to Take Control of Their Health](#)
- May 10, 2017*  
[Mylan Reports First Quarter 2017 Results](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 1, 2017*  
[Annual Report \(10-K\)](#)
- May 23, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016*  
[Quarterly Report \(10-Q\)](#)